Preliminary Programme

TimeTitleSpeakers
14.00 - 15.00SESSION 1 - MULTIDISCIPLINARY EDUCATIONAL SESSION – MTD TEAM’S RESPONSE IN TIMES OF DISASTER/CRISISCHAIR: JAN BLATNY
14.00 - 14.10The Katrina disaster and haemophiliaCindy Leissinger
14.10 - 14.20Nurses response
14.20 - 14.30Physiotherapists response
14.30 - 14.40WFH response to natural disastersAssad Haffar
14.40 - 14.50Preparing for the next disaster
14.50 - 15.00LIVE Q&A
15.00 - 15.15BREAK
15.15 - 16.15SESSION 2 – REPLACEMENT THERAPYCHAIR: HERVE CHAMBOST
15.15 - 15.30Which criteria to choose the timing and the product to introduce FVIII in severe haemophilia AChristoph Königs
15.30 - 15.45Immunogenicity of Factor VIIISebastien Lacroix-Desmazes
15.45 - 16.00Are all Factor IX concentrates equal?Cedric Hermans
16.00 - 16.15LIVE Q&A
16.15 - 16.30BREAK
16.30 - 17.30SESSION 3 – NON-REPLACEMENT THERAPIESCHAIR: DAN HART
16.30 - 16.45Current and future productsPeter Collins
16.45 - 17.00Can we personalise dosing for non-replacement therapies?Pal André Holme
17.00 - 17.15Thrombosis and the novel haemophilia therapies
17.15 - 17.30LIVE Q&A
17.30 - 17.45BREAK
18.00 - 19.00SATELLITE SYMPOSIA 4, 5, 6
19.00 - 19.15BREAK
19.15 - 19.50RECAP OF THE DAY – WEDNESDAYCHAIR: ROBERT KLAMROTH
19.15 - 19.30RECAP OF THE DAY
19.30 - 19.50OPEN DISCUSSION AND LIVE Q&A
TimeTitleSpeakers
14.00 - 15.00SESSION 4 – GENE THERAPYCHAIR: WOLFGANG MIESBACH
14.00 - 14.15Current status – Efficacy and safetyPaul Batty
14.15 - 14.30Liver disease In haemophilia and impact on gene therapyHeiner Wedemeyer
14.30 - 14.45Future prospects for non-AAV gene and cell therapyThierry Vandendriessche
14.45 - 15.00LIVE Q&A
15.00 - 15.15BREAK
15.15 - 16.15SESSION 5 - VON WILLEBRAND DISEASECHAIR: FARIBA BAGHAEI
15.15 - 15.30Women health in von Willebrand diseaseRiitta Lassila
15.30 - 15.45Prophylaxis in von Willebrand disease – How and Who?Eugenia Biguzzi
15.45 - 16.00Acquired von Willebrand diseaseSophie Susen
16.00 - 16.15LIVE Q&A
16.15 - 16.30BREAK
16.30 - 17.30SESSION 6 – DELIVERY OF CARECHAIR: ANA BOBAN
16.30 - 16.45European adoption of the von Willebrand disease guidelinesFrank Leebeek
16.45 - 17.00European accreditation of haemophilia and gene therapy centresAna Boban
17.00 - 17.15EUHASS UpdateMichael Makris
17.15 - 17.30LIVE Q&A
17.30 - 18.00BREAK
18.00 - 19.00SATELLITE SYMPOSIA 7, 8, 9
19.00 - 19.15BREAK
19.15 - 19.50RECAP OF THE DAY – THURSDAYCHAIR: FLORA PEYVANDI
19.15 - 19.30RECAP OF THE DAY
19.30 - 19.50OPEN DISCUSSION AND LIVE Q&A
TimeTitleSpeakers
14.00 - 15.00SESSION 7 - SLAMCHAIR: ROBERT KLAMROTH
14.00 - 14.426 SLAM PRESENTATIONS
14.42 - 15.00LIVE Q&A
15.00 - 15.15BREAK
15.15 - 15.45SESSION 8 - AROSENIUS LECTURECHAIR: MARÍA TERESA ALVAREZ-ROMÁN

15.15 - 15.45

What is the "true" rate of inhibitor development in haemophilia?Rolf Ljung
15.45 - 16.05SESSION 9 - EAHAD SUPPORTED RESEARCHCHAIR: KARIN FIJN VAN DRAAT

15.45 - 15.55

"DEVELOPMENT OF A NOVEL GENE THERAPY APPROACH FOR GLANZMANN THROMBASTHENIA (GT): ASSESSMENT IN CRISPR GT CELL MODEL, GT PATIENT PROGENITOR CELLS, AND NBSGW IMMUNODEFICIENT MICE" - 2020 RESEARCH GRANT PROJECT REPORTJose Rivera

15.55 - 16.05

"GETTING GRIP ON TOLERANCE: THE ROLE OF FC GAMMA RECEPTORS IN IMMUNE TOLERANCE TO PROTEIN THERAPEUTICS"Samantha Gouw
16.05 - 16.20BREAK
16.20 - 17.20SESSION 10 - LATEST CLINICAL TRIAL RESULTSCHAIR: FLORA PEYVANDI
16.20 - 17.026 LATEST CLINICAL TRIAL RESULTS PRESENTATIONS
17.02 - 17.20LIVE Q&A
17.20 - 18.00BREAK
18.00 - 19.00SATELLITE SYMPOSIA 10, 11, 12
19.00 - 19.15BREAK
19.15 -  19:50RECAP OF THE DAY – FRIDAYCHAIR: MIKE MAKRIS
19.15 - 19.30RECAP OF THE DAY
19.30- 19.50OPEN DISCUSSION AND LIVE Q&A